CD274 and non-small cell lung carcinoma: We conjecture that it may be similar to how PDL1 positivity predicts response to pembrolizumab therapy (albeit imperfectly), as previous trials have utilized different cutoffs for PD-L1 positivity in NSCLC [39,40,41].